{"filings":[{"id":2198517,"accession_number":"0001193125-26-345672","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-08-12T10:30:26+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Annexon Q2 net loss $55.3M; BLA for tanruprubart on track for Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $55.3M ($0.28/share) vs $49.2M ($0.34) year ago; R&D $46.6M, G&A $10.6M.","Cash $209.2M plus $200M credit facility ($50M drawn) extends runway into 2028.","Tanruprubart BLA submission for GBS expected Q4 2026; EU MAA under review.","Vonaprument Phase 3 ARCHER II adds Month 24 dual primary endpoint; Month 15 data on track Q4 2026.","ANX1502 POC data in CAD expected Fall 2026; Mark Blumenkranz appointed to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2163399,"accession_number":"0001193125-26-342524","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-08-10T20:35:51+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Annexon appoints Mark Blumenkranz to board; Muneer Satter steps down after 11 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark S. Blumenkranz appointed to Annexon board effective Aug 10, 2026, as Class II director with term to 2028 annual meeting.","He joins Audit Committee and Science and Technology Committee; receives $40k annual retainer and 175k-share initial option grant.","Muneer Satter resigned as director and committee roles effective immediately prior to Blumenkranz appointment; no disagreement cited.","Blumenkranz is Stanford emeritus professor; co-founded Adverum, Optimedica, Oculeve, Kedalion; retinal expertise relevant to vonaprument."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2088676,"accession_number":"0001193125-26-336867","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-08-06T12:17:10+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon reports all 10 GBS patients in FORWARD study improved within days on tanruprubart","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 patients showed rapid, clinically meaningful muscle strength improvement within 4 days of single 30 mg/kg infusion.","Four bedbound patients walked with/without assistance between day 2 and day 8; one ventilated patient off ventilator within 4 days.","Results consistent with Phase 3 data where ~90% improved by day 8; tanruprubart generally well-tolerated.","BLA submission targeted for Q4 2026; MAA under EMA review; GBS has ~22,000 annual U.S./Europe cases and >$20B U.S. burden.","CEO cites decade-long commitment to C1q-targeted approach for neuroinflammatory diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1968517,"accession_number":"0001193125-26-326199","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-07-30T20:25:02+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Annexon secures up to $200M credit facility from Oxford Finance; draws $50M initially","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $200M term loan facility with Oxford Finance; initial $50M drawn on July 30, 2026.","Additional $100M available upon milestones for vonaprument and tanruprubart programs; $50M uncommitted tranche subject to lender approval.","Floating interest rate: greater of 1-month SOFR+4.6% or 7.60% per annum.","Maturity July 2031 or June 2032 depending on milestones; interest-only period through Sept 2029 (extendable).","Proceeds for working capital and general business; secured by substantially all assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-30","daily_digest_url":"/daily/2026-07-30","daily_digest_rank":9},{"id":1027678,"accession_number":"0001193125-26-269479","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-06-12T20:16:03+00:00","items":["5.07"],"status":"ready","headline":"Annexon shareholders approve increase in authorized shares from 300M to 500M and elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors Bettina M. Cockroft, M.D. (101,594,745 for) and Douglas Love, Esq. (107,491,451 for).","Ratified KPMG LLP as independent auditor for FY 2026 with 142,016,122 votes for, 185,546 against.","Advisory vote on executive compensation approved with 122,347,513 for, 1,986,387 against.","Approved amendment to certificate of incorporation to increase authorized shares of common stock from 300M to 500M with 129,051,256 for, 4,374,799 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93448,"accession_number":"0001193125-26-211863","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q1 net loss $44.1M ($0.23/sh); cash $225M; GA Ph3 data Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.1M (-$0.23/sh) vs $54.4M (-$0.37/sh) Q1 2025; R&D $35.8M, G&A $10.3M.","Cash $225M as of March 31, 2026; expected runway into H2 2027.","Topline Phase 3 ARCHER II data for vonaprument in GA expected Q4 2026.","Tanruprubart MAA under EMA review; BLA submission with FORWARD data planned 2026.","ANX1502 proof-of-concept data in CAD anticipated in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105071,"accession_number":"0001193125-26-131746","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon reports Q4 and FY2025 net loss of $48.3M and $208.5M; cash $238.3M; vonaprument Phase 3 data due Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025 $48.3M ($0.28/sh) and FY2025 $208.5M ($1.34/sh); FY2024 net loss was $138.2M.","Cash, equivalents and short-term investments $238.3M at Dec 31, 2025; funds operations into H2 2027.","R&D expenses $184.7M for FY2025, up from $119.4M due to Phase 3 ARCHER II and regulatory filings.","Vonaprument Phase 3 ARCHER II topline data in geographic atrophy expected Q4 2026; enrollment completed July 2025.","Tanruprubart MAA filed in EU for GBS; U.S. BLA submission planned in 2026 based on FORWARD study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105070,"accession_number":"0001193125-26-054695","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chairman Thomas G. Wiggans to retire from Annexon board at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mr. Wiggans notified the Board on Feb 12, 2026 of his intent to retire and not stand for reelection.","His term as director will end at the 2026 annual meeting; he remains Chairman and committee member until then.","Resignation is not the result of any disagreement with the Company on operations, policies, or strategy.","Mr. Wiggans served on the Board for eight years; management and Board expressed gratitude."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105069,"accession_number":"0001193125-26-012918","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annexon furnishes updated corporate presentation with no specific material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company updated its corporate presentation for use at the 44th Annual J.P. Morgan Healthcare Conference on Jan 14, 2026.","Presentation is furnished as Exhibit 99.1, but the excerpt provided contains no new financial or pipeline data.","No earnings, guidance, or clinical milestones are reported in the furnished materials.","The filing is a routine Regulation FD disclosure with no substantive quantitative updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105068,"accession_number":"0001193125-26-009740","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon outlines 2026 milestones: GBS MAA filed, GA Phase 3 data H2 2026, oral C1 inhibitor data expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tanruprubart MAA filed in Europe for Guillain-Barré syndrome; U.S. BLA submission with FORWARD data planned in 2026.","Vonaprument Phase 3 ARCHER II topline data for geographic atrophy expected second half of 2026; enrolled 659 patients.","ANX1502 proof-of-concept data in cold agglutinin disease (CAD) anticipated in 2026; oral C1 inhibitor.","Financial position funds operations into late 2027, well past anticipated key milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121318,"accession_number":"0001193125-25-283191","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Annexon closes $86.25M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 25,096,153 shares at $2.60/share and 3,750,000 pre-funded warrants at $2.599 each.","Underwriters' option for 4,326,922 additional shares exercised in full; total gross $86.25M.","Net proceeds of approximately $80.4M after underwriting discounts and expenses.","Offering closed on November 14, 2025; pre-funded warrants exercisable at $0.001 per share.","Goldman Sachs, TD Cowen, and Wells Fargo acted as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121317,"accession_number":"0001193125-25-274220","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon posts Q3 net loss $54.9M, extends cash runway to late Q1 2027; GBS MAA filing on track for Jan 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $54.9M ($0.37 per share) in Q3 2025, compared to net loss $34.8M ($0.25 per share) in Q3 2024.","R&D expenses $49.7M, up from $30.1M, driven by Phase 3 ARCHER II trial and global GBS regulatory filings.","Cash and equivalents $188.7M as of Sep 30, 2025; operations funded into late Q1 2027 through key milestones.","Tanruprubart (ANX005) GBS MAA submission on track for Jan 2026; FDA discussions on BLA generalizability package ongoing.","Vonaprument (ANX007) Phase 3 ARCHER II trial enrolled 659 GA patients; topline data expected second half 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137973,"accession_number":"0000950170-25-108859","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q2 net loss $49.2M; tanruprubart MAA submission Q1 2026, ARCHER II topline H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.2M ($0.34/share) in Q2 2025 vs $29.6M ($0.23) in Q2 2024; R&D $44.2M.","Cash and equivalents $227.0M as of June 30, 2025; runway into Q4 2026.","Tanruprubart MAA for GBS submission expected Q1 2026; FDA BLA discussions ongoing.","Vonaprument ARCHER II Phase 3 enrollment completed (659 patients); topline data H2 2026.","ANX1502 oral C1s inhibitor POC trial update in CAD anticipated by year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155360,"accession_number":"0001193125-25-147005","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"Annexon extends 2022 common warrants to June 2026, cash exercise only at $5.806875","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrants exercisable for up to 6,877,622 shares of common stock.","Term extended by one year to June 30, 2026; cash exercise only at $5.806875/share.","Potential aggregate proceeds of up to $39.9 million if all warrants exercised.","Amendment entered with certain holders of the 2022 common stock purchase warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155359,"accession_number":"0001193125-25-137810","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annexon stockholders elect Class II directors and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class II directors Jung E. Choi and William D. Waddill elected with 83,207,282 and 62,741,842 votes for, respectively.","Ratification of KPMG as independent auditor for FY2025 passed with 98,033,809 votes for, 124,245 against.","Advisory vote on named executive officer compensation approved with 79,754,521 for, 3,796,829 against, 3,296,805 abstentions.","Broker non-votes totaled 11,334,985 on director elections and advisory compensation vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155358,"accession_number":"0000950170-25-069156","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q1 net loss $54.4M; cash $263.7M; GBS, GA programs advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $54.4M ($0.37/share) vs $25.2M ($0.21/share) in Q1 2024; R&D expense $48.2M, up from $21.0M.","Cash and short-term investments $263.7M; runway into H2 2026.","FDA meeting for tanruprubart (ANX005) in GBS scheduled Q2 2025; open-label FORWARD study starting Q2 2025; BLA submission planned.","Phase 3 ARCHER II for ANX007 in dry AMD with GA enrollment completion expected Q3 2025; top line data H2 2026.","Proof-of-concept trial for oral C1s inhibitor ANX1502 in cold agglutinin disease anticipated completion mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173875,"accession_number":"0000950170-25-030824","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon reports Q4 2024 net loss $48.6M; cash $312M; key pipeline milestones for GBS and dry AMD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $312.0M as of Dec 31, 2024; runway into 2H 2026.","Net loss $48.6M Q4 2024 vs $27.9M Q4 2023; R&D expense $43.4M.","Pre-BLA meeting for GBS drug ANX005 targeted 1H 2025; BLA submission planned.","Global registration path for ANX007 in dry AMD with GA; Phase 3 ARCHER II data expected 2H 2026.","ANX1502 oral C1s inhibitor POC trial ongoing; dataset in up to 7 CAD patients expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173874,"accession_number":"0001193125-25-005009","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon provides 2025 outlook; targets BLA submission for ANX005 in GBS in 1H 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANX005 for GBS: Phase 3 showed rapid muscle strength improvement vs placebo; BLA submission targeted for 1H 2025.","ANX007 for GA: Phase 3 ARCHER II enrollment on track for completion in 2H 2025; data expected 2H 2026.","ANX1502 oral C1s inhibitor: clinical proof-of-concept data in CAD expected in 1Q 2025.","Cash runway sufficient into 2H 2026 to achieve key milestones.","Positive Phase 2 ARCHER data for ANX007 showed significant vision preservation on BCVA and LLVA endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173873,"accession_number":"0001193125-25-004133","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Annexon appoints commercial executive William 'BJ' Jones to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William 'BJ' Jones appointed to Board as Class I director effective Jan 9, 2025, term through 2027 annual meeting.","Receives $40K annual retainer, initial 88K-share option (3-yr monthly vest), and 44K-share annual option.","Jones brings 30 years commercial launch experience; currently CCO at NewAmsterdam Pharma; previously at Biohaven (acquired by Pfizer for $11.6B).","Company notes his expertise valuable as ANX005 (Guillain-Barré Syndrome) and ANX007 (geographic atrophy) approach commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190845,"accession_number":"0001193125-24-279038","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon positive real-world evidence study of ANX005 in Guillain-Barré Syndrome shows benefit over IVIg/PE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANX005 30 mg/kg showed faster improvement in muscle strength vs matched IVIg/PE cohort at week 1 (p<0.0001).","Patients on ANX005 ~2x more likely to be in better health on GBS-Disability Scale at week 8 (p=0.0459).","Fewer ANX005 patients required mechanical ventilation (15/79 vs 32/79, p=0.022); 12 fewer median days on ventilation and in ICU.","Planned U.S. Biologics License Application submission for ANX005 in GBS in first half 2025.","Study used propensity-score matching between Phase 3 patients (n=79) and IGOS global registry patients (n=79)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190844,"accession_number":"0000950170-24-127027","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q3 net loss $34.8M; cash $340M; ANX005 BLA on track for H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.8M ($0.25/share) vs $32.5M ($0.43) in Q3 2023.","Cash and investments $340.1M, expected to fund operations into H2 2026.","R&D expenses rose to $30.1M from $27.9M, driven by GBS, GA, and ANX1502 programs.","ANX005 GBS: topline RWE comparability data expected year-end 2024; BLA submission targeted H1 2025.","Strengthened commercial and medical affairs leadership with three senior appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190843,"accession_number":"0001193125-24-240585","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon reports Phase 2 ANX007 data: 0% vision loss in less advanced GA vs 17% sham","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANX007 monthly-treated patients with less advanced dry AMD lost 0% (0/56) 15+ letters vs 17% (10/59) sham (p=0.0013).","In overall Phase 2 ARCHER, ANX007 monthly reduced 15+ letter loss to 6% (5/89) vs 21% (19/89) sham (p=0.0021).","ANX007 showed 61% decrease in EZ loss in patients with <80% EZ intact at baseline (p=0.0575).","Pivotal Phase 3 ARCHER II data expected in second half 2026.","ANX007 is a first-in-kind Fab targeting C1q intravitreally; data presented at AAO 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207324,"accession_number":"0000950170-24-095073","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q2 2024 net loss narrowed to $29.6M; cash $368.7M, runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.6M ($0.23/shr) vs. $35.2M ($0.47/shr) in Q2 2023.","Cash, equivalents and short-term investments $368.7M as of June 30, 2024; runway into H2 2026.","ANX005 (GBS) Phase 3 met endpoints; RWE topline data expected year-end 2024; BLA filing H1 2025.","ANX007 (GA) Phase 3 ARCHER II trial dosing initiated; topline data expected H2 2026.","ANX1502 oral C1s inhibitor bridging study to tablet completed; POC data in CAD expected Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207323,"accession_number":"0001193125-24-193404","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon initiates Phase 3 ARCHER II GA trial; Phase 2 data show vision protection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosing started in global pivotal Phase 3 ARCHER II trial of ANX007 for geographic atrophy (GA).","Topline data expected in second half of 2026; trial to enroll ~630 patients.","Phase 2 ARCHER: ANX007 reduced ≥15-letter BCVA loss to 5.6% vs sham 21.3% (p=0.0021).","Structural protection: up to 60% photoreceptor preservation in central fovea (p=0.0319).","FDA/EMA aligned on BCVA as primary endpoint; EU PRIME and US Fast Track designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224731,"accession_number":"0001193125-24-167962","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon Phase 3 trial of ANX005 meets primary endpoint; GBS patients recover faster","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint at Week 8: 2.41-fold higher likelihood of better health state (p=0.0058).","ANX005 patients walked 31 days earlier and came off ventilation 28 days earlier vs placebo.","At Week 26, 21.5% of ANX005 patients fully recovered (GBS-DS=0) vs 8.6% on placebo (OR 4.14, p=0.0092).","Subgroup with North American/European baseline characteristics showed 3x greater likelihood of better health state at Week 8.","Single infusion generally well-tolerated; safety profile similar to placebo, no increased infections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224730,"accession_number":"0001193125-24-159748","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annexon stockholders elect Class I directors, ratify KPMG, and approve say-on-pay at 2024 Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected William H. Carson, M.D. (78,919,065 for, 597,431 withheld) and Muneer A. Satter (60,965,423 for, 18,551,073 withheld) as Class I directors.","Ratified KPMG LLP as independent auditor for fiscal 2024 with 84,114,097 for, 36,225 against, 8,491 abstain.","Advisory vote on named executive officer compensation approved: 77,548,918 for, 1,895,328 against, 72,250 abstain.","Broker non-votes were 4,642,317 for director election and say-on-pay; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224729,"accession_number":"0001193125-24-157454","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Annexon prices $125M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 13,001,120 shares at $6.25/sh and 7M pre-funded warrants at $6.249/sh; gross proceeds $125M.","Net proceeds expected ~$116.9M after underwriting discounts and expenses; offering closed June 7, 2024.","Underwriters granted 30-day option to purchase up to 3,000,168 additional shares.","J.P. Morgan, Jefferies, TD Cowen, BofA Securities and Wells Fargo Securities served as joint book-running managers.","Funds will support development of classical complement-mediated neuroinflammatory therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224728,"accession_number":"0001193125-24-153625","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Annexon Phase 3 GBS trial meets primary endpoint; ANX005 shows 2.4-fold improvement on GBS-DS at week 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial met primary endpoint: single infusion of ANX005 30 mg/kg achieved 2.4-fold improvement on GBS-DS at week 8 (p=0.0058).","Key secondary endpoints met: 28 fewer days on ventilation (p=0.0356), 31-day reduction in time to walk independently (p=0.0211), and early muscle strength gains.","ANX005 was generally well-tolerated; most adverse events mild-to-moderate, no drug-related deaths or serious infections.","RWE comparability protocol initiated with IGOS; BLA submission and RWE data expected first half 2025.","GBS affects >22,000 hospitalized annually in U.S./Europe; no FDA-approved treatments currently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224727,"accession_number":"0000950170-24-058629","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q1 net loss $25.2M; cash $264.9M; Phase 3 GBS data due Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.2M ($0.21/share) vs $38.7M ($0.52) in Q1 2023; R&D spend $21M vs $32.3M.","Cash, equivalents & short-term investments $264.9M as of March 31, 2024, runway into mid-2026.","Topline Phase 3 data for ANX005 in Guillain-Barré Syndrome expected Q2 2024.","Pivotal Phase 3 ARCHER II trial for ANX007 in geographic atrophy to start mid-2024; ARROW head-to-head vs SYFOVRE planned H2 2024.","Proof-of-concept data for oral ANX1502 in cold agglutinin disease on track for H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224726,"accession_number":"0001193125-24-133086","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon presents positive Phase 2 data for ANX007 in GA; plans Phase 3 trials in 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANX007 showed 73% relative risk reduction in BCVA 15-letter loss at 12 months in Phase 2 ARCHER trial.","Statistically significant slowing of low luminance visual acuity loss and reduction in photoreceptor loss observed.","No choroidal neovascularization increase and no cases of vasculitis; generally well-tolerated safety profile.","Global pivotal Phase 3 ARCHER II (vs sham) expected mid-2024; Phase 3 ARROW (vs SYFOVRE) expected H2 2024.","Preclinical data show C1q blockade protects photoreceptor synapses and preserves retinal function in GA models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243996,"accession_number":"0000950170-24-036399","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon reports Q4 2023 net loss $27.9M; cash $259.7M; Phase 3 GBS data Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 $134.2M vs $141.9M in prior year; R&D spend $113.8M.","Cash and short-term investments $259.7M as of Dec 31, 2023; runway into mid-2026.","Phase 3 ANX005 GBS topline data expected Q2 2024; BLA submission supported by RWE from IGOS.","Phase 3 ANX007 GA ARCHER II trial (sham-controlled) to initiate mid-2024; ARROW head-to-head vs SYFOVRE planned H2 2024.","Completed $125M financing in December 2023 extending operating runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243995,"accession_number":"0001193125-24-058031","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annexon holds virtual R&D Day focusing on Guillain-Barré Syndrome program","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation highlighted serious unmet need in Guillain-Barré Syndrome and Annexon's novel therapeutic approach.","Webcast archive available on investor page for 30 days; CEO Douglas Love presented.","No financial results, guidance, or clinical data disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243994,"accession_number":"0001193125-24-004387","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annexon outlines 2024 clinical milestones: Phase 3 GBS data H1 2024, GA trial start mid-2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 pivotal data for ANX005 in Guillain-Barré syndrome on track for first half of 2024; potential first approved treatment in U.S.","Global pivotal program for ANX007 in geographic atrophy (ARCHER II) to initiate mid-2024 with vision preservation as primary endpoint","Proof-of-concept study for oral C1s inhibitor ANX1502 in cold agglutinin disease to start first half of 2024","Completed $125 million financing extends operating runway into second quarter 2026","ANX007 received PRIME designation in EU; to launch head-to-head ARROW trial vs. SYFOVRE in late 2024"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261397,"accession_number":"0001193125-23-302246","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K/A","filed_at":"2023-12-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Annexon raises ~$125M via public offering of 25M shares and 18.4M pre-funded warrants at $2.88","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 25,035,000 common shares at $2.88/share and 18,379,861 pre-funded warrants at $2.879 each.","Gross proceeds expected to be ~$125M before underwriting discounts and expenses.","Underwriters: Jefferies LLC and Cowen and Company, LLC; closing expected December 26, 2023.","Pre-funded warrants exercisable immediately but subject to 9.99% beneficial ownership limitation (waivable to 19.99%).","Offering conducted under shelf registration statement on Form S-3 (File No. 333-258863)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261402,"accession_number":"0001193125-23-301190","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Annexon prices $125M underwritten offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds expected ~$125M from 25,035,000 shares at $2.880 and 18,379,861 pre-funded warrants at $2.879.","Closing expected December 26, 2023; Jefferies and TD Cowen act as joint book-running managers.","Pre-funded warrants exercisable immediately; holder limited to 9.99% beneficial ownership unless increased.","Offering dilutes existing shareholders; shares and warrants represent ~43M shares if fully exercised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261401,"accession_number":"0001193125-23-300035","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA aligns with Annexon on vision preservation endpoint for ANX007 GA Phase 3 program; ANX1502 Ph1 positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA agrees to prevention of ≥15-letter BCVA loss as primary endpoint; no requirement for surrogate structural endpoint.","Two Phase 3 trials: ARCHER II (sham-controlled, ~400 pts, starts mid-2024) and ARROW (head-to-head vs Syfovre, ~500 pts, starts late 2024).","ANX007 Phase 2 ARCHER showed 72% risk reduction (p=0.006) in BCVA ≥15-letter loss in monthly dose arm vs sham.","ANX1502 Phase 1 healthy-volunteer data: target drug levels with BID dosing, suppressed C4d biomarker, no serious AEs.","Company plans to advance tablet formulation of ANX1502 into proof-of-concept trial in CAD patients in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261400,"accession_number":"0000950170-23-062943","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q3 net loss $32.5M, cash $165.3M; Phase 3 GBS enrollment complete, data H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.5M ($0.43 per share) vs $35.1M ($1.42 per share) in Q3 2022.","Cash, equivalents and investments of $165.3M as of Sep 30, 2023; runway into Q2 2025.","R&D expenses flat at $27.9M; G&A down to $6.9M from $8.2M.","Phase 3 GBS trial enrolled 225 patients; topline pivotal data expected first half 2024.","ANX007 for GA granted EMA PRIME designation; global Phase 3 regulatory discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261399,"accession_number":"0001193125-23-261704","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EMA grants PRIME designation for Annexon's ANX007 in geographic atrophy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PRIME designation based on Phase 2 ARCHER trial showing preservation of visual function.","ANX007 is the first therapeutic candidate for GA to receive EMA PRIME designation.","Company engaging with U.S. and EU regulators to design global Phase 3 program.","Designation provides enhanced EMA support to expedite development and review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261398,"accession_number":"0001193125-23-254189","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EMA grants orphan drug designation to ANX005 for GBS; Phase 3 enrollment complete","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Medicines Agency granted orphan drug designation to ANX005 for Guillain-Barré Syndrome.","Target enrollment of 225 patients achieved in Phase 3 pivotal study of ANX005 in GBS.","Company on track to report topline Phase 3 data in first half of 2024.","EMA stated preliminary data show 'clinically relevant advantage' over intravenous immunoglobulin.","Orphan designation includes 10 years of EU market exclusivity and reduced regulatory fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278640,"accession_number":"0000950170-23-039072","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q2 net loss $35.2M; GA visual function data; GBS enrollment completion in H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ANX007 (GA) ARCHER Phase 2 data showed dose-dependent preservation of visual function; regulatory engagement planned.","Phase 3 pivotal trial of ANX005 in GBS enrollment to complete in H2 2023; topline results expected H1 2024.","Appointed Jamie Dananberg, M.D., as CMO; brings >20 years of drug development experience.","Cash and equivalents $192.9M as of June 30, providing runway into 2025. Q2 net loss $35.2M ($0.47 per share).","Upcoming catalysts: ANX1502 Phase 1a data (H2 2023), ANX009 LN Phase 1b data, ALS Phase 2a data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278639,"accession_number":"0001193125-23-199158","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Annexon appoints Jamie Dananberg as CMO; ARCHER trial shows ANX007 vision protection in GA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jamie Dananberg, M.D., appointed chief medical officer; previously CMO at UNITY Biotechnology and exec at Takeda and Eli Lilly.","ARCHER Phase 2 trial in geographic atrophy showed ANX007 provided dose-dependent, statistically significant protection from vision loss (BCVA ≥15 letters).","Primary endpoint of GA lesion growth rate did not reach significance; additional analyses show trend toward greater effect in second six months.","ANX007 was well-tolerated with no increase in CNV or retinal vasculitis; company to discuss regulatory path with FDA later this year.","Fellow-eye analysis showed 74% (monthly) and 47% (every-other-month) reduction in BCVA loss vs sham; off-treatment data support on-treatment benefit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296856,"accession_number":"0001193125-23-164462","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annexon announces 2023 annual meeting voting results; all proposals approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Bettina Cockroft, Douglas Love, Thomas Wiggans re-elected with >32.4 M votes for each.","Ratification of KPMG as independent auditor for FY2023: 46.67 M for, 22.6 K against, 41.1 K abstain.","Advisory say-on-pay approved with 43.67 M for, 101.2 K against, 44.1 K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296855,"accession_number":"0001193125-23-153420","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annexon ARCHER Ph2: ANX007 shows stat-sig vision loss protection, primary lesion growth endpoint missed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANX007 monthly reduced risk of ≥15-letter BCVA loss by 72% (p=0.006); pooled 59% (p=0.008).","Primary endpoint GA lesion growth rate reduction not met: monthly 6.2% (p=0.526), EOM 1.3% (p=0.896).","ANX007 well-tolerated; 3 SAEs endophthalmitis (injection-related), 3 SAEs intraocular inflammation suspected treatment-related.","First complement therapy to show preservation of visual function in a prospective 12-month GA trial.","Company plans regulatory engagement for optimal path forward; webcast today 1:30pm PT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296854,"accession_number":"0000950170-23-018810","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon reports Q1 net loss $38.7M; pipeline milestones expected through 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.7M ($0.52/sh) vs $35.4M ($0.92/sh) in Q1 2022; R&D spend rose to $32.3M.","Cash and investments $228.2M; runway into 2025 for ongoing trials.","Phase 2 ARCHER trial of ANX007 in geographic atrophy data expected mid-2023.","Phase 3 GBS trial enrollment completion 2H'23; topline results 1H'24.","Initial Phase 1b data for ANX009 in lupus nephritis due 1H'23; ANX1502 oral data 2H'23."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317221,"accession_number":"0001193125-23-067918","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Annexon discloses $0.5M in SVB deposits; 0.2% of total cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Silicon Valley Bank closed by FDIC on March 10, 2023.","Annexon held ~$0.5 million in SVB deposit accounts.","Exposure equals approximately 0.2% of total cash, cash equivalents and marketable securities.","Company expects no material impact on operations or liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317220,"accession_number":"0000950170-23-006240","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon reports Q4 2022 net loss of $34.4M; cash runway into 2025; reiterates pipeline milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.4M for Q4 2022 ($141.9M full year) vs $37.4M Q4 2021.","Cash and equivalents $242.7M as of Dec 31, 2022; expected to fund operations into 2025.","R&D expenses $28.5M in Q4 2022 ($112.5M full year) vs $27.2M Q4 2021.","Phase 2 trial of ANX007 in geographic atrophy on track for initial data mid-2023.","Phase 1 MAD trial of ANX1502 initiated; proof-of-concept in CAD planned for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317219,"accession_number":"0001193125-23-004050","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Annexon prioritizes 4 flagship complement programs; GBS Phase 3 enrollment expanded to 220 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANX005 Phase 3 in GBS expanded to 220 patients; pivotal data expected H1 2024.","ANX005 Phase 2/3 pivotal in Huntington's to initiate in 2023.","ANX007 Phase 2 in geographic atrophy on track for initial data mid-2023.","Cash $269.5M as of Sep 30, 2022; operating runway updated to into 2025.","Deprioritizing wAIHA; advancing ANX1502 (oral small molecule) into MAD study H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317218,"accession_number":"0001193125-23-002932","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Annexon appoints Dr. Rick Artis as Chief Scientific Officer, succeeding Dr. Larry Mattheakis","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dean 'Rick' Artis, Ph.D., appointed CSO effective January 6, 2023, succeeding Larry C. Mattheakis who is departing.","Artis previously served as SVP of Chemistry at Annexon and discovered small molecule ANX1502.","Artis most recently was CSO at Octant Bio and has discovery-to-clinic experience across multiple therapeutic areas.","He will lead all research efforts with focus on expanding small molecule pipeline and advancing complement portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335501,"accession_number":"0000950170-22-021512","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon reports Q3 2022 net loss of $35.1M, cash $269.5M; pipeline updates in Jan 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $35.1M ($0.51 per share) vs $35.6M ($0.93 per share) in Q3 2021.","Cash & equivalents $269.5M as of Sep 30, 2022; runway into H2 2025.","R&D expenses $27.9M and G&A $8.2M, both essentially flat year-over-year.","Portfolio updates across autoimmune, neurodegeneration and ophthalmology franchises planned for Jan 2023.","ANX005 HD Phase 2 data shows reduced neuroinflammation; regulator engagement by year-end; ANX007 GA Phase 2 data expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352913,"accession_number":"0000950170-22-015569","cik":1528115,"company_name":"Annexon, Inc.","ticker":"ANNX","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annexon Q2 net loss $37.1M; cash $177.6M, extended runway into H2 2025 via $130M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $37.1M ($0.96/share) vs. $31.3M ($0.82/share) in Q2 2021.","Cash and short-term investments $177.6M at June 30, 2022, plus $130M from July private placement.","Operating runway extended into second half of 2025.","FDA granted Fast Track designation to ANX007 for geographic atrophy; Phase 2 enrolled.","Phase 1 trials initiated for oral small molecule ANX1502 and next-gen mAb ANX105."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":883930423.6261597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-08T23:59:59+00:00|352913"}